Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced the first patient has been dosed in its Phase 1/2 clinical trial for CFT1946, a targeted therapy for BRAF V600 mutant solid tumors. This marks the first degrader to enter clinical development aimed at BRAF-driven cancers, generally treated with limited options once resistance develops. Early studies indicate CFT1946 may offer deeper and more durable efficacy than current BRAF inhibitors. The trial will assess safety and effectiveness, progressing to evaluate CFT1946 both alone and with trametinib in advanced phases. This initiative expands C4T's oncology programs via its proprietary TORPEDO® platform.
C4 Therapeutics (Nasdaq: CCCC) reports continued progress in its oncology trials, with key updates expected in 2023. The company is advancing CFT7455 and CFT8634, focusing on multiple myeloma and synovial sarcoma treatments. Phase 1 dose escalation data for both drugs will be shared in the second half of 2023. Additionally, CFT1946 targeting BRAF-V600 mutations has initiated trials. As of September 30, 2022, C4T holds $366 million in cash, enough to fund operations into 2024. A presentation at the J.P. Morgan Healthcare Conference is also scheduled.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 am PST (1:30 pm EST) in San Francisco. The event will be accessible via a live webcast on the company’s website, with a replay available for two weeks afterward. C4T focuses on targeted protein degradation to develop innovative medicines for difficult-to-treat diseases, leveraging its TORPEDO® platform to enhance patient outcomes.
C4 Therapeutics (Nasdaq: CCCC) reported a net loss of $32 million for Q3 2022 compared to $24.7 million in Q3 2021. Total revenue decreased to $6.8 million from $8.5 million, driven by collaborative agreements. R&D expenses rose to $29.7 million, primarily due to ongoing clinical trials for CFT7455 and CFT8634. They achieved IND clearance for CFT1946, a significant milestone expected to lead to Phase 1/2 trial initiation by year-end. Cash and marketable securities as of September 30, 2022, stood at $366 million, sufficient to fund operations until the end of 2024.
C4 Therapeutics (Nasdaq: CCCC) has received FDA approval to proceed with a Phase 1/2 trial for its drug CFT1946, targeting BRAF-V600 mutant solid tumors like lung, colorectal, and melanoma. This marks C4T's third successful oncology investigational new drug application in under two years. CFT1946 aims to provide deeper and more durable responses compared to existing BRAF inhibitor treatments. The trial will primarily assess safety, tolerability, and anti-tumor activity, with initial evaluations involving CFT1946 as a single agent and later in combination with trametinib.
C4 Therapeutics (Nasdaq: CCCC) announced participation in the Bank of America Securities Precision Oncology Conference 2022. The event will occur on October 3, 2022, at 9:50 a.m. ET. C4T focuses on advancing targeted protein degradation science to develop innovative small-molecule medicines aimed at improving patient outcomes in oncology. The presentation will be available via live webcast on the company's website, with an archived replay accessible for 30 days post-event. C4T is leveraging its TORPEDO® platform to tackle challenging diseases.
C4 Therapeutics (Nasdaq: CCCC) reported a 40% increase in total revenue to $13.8 million for Q2 2022, up from $9.8 million in Q2 2021, driven by collaboration agreements. The company incurred a net loss of $27.4 million, leading to a net loss per share of $0.56. C4T continues to advance its pipeline with CFT7455 and CFT8634 in Phase 1/2 trials. The company maintains a strong cash position of $397.8 million, projected to fund operations through the end of 2024.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has appointed Dr. Laura Bessen and Dr. Donna Grogan to its board of directors, enhancing its leadership as it advances targeted protein degradation science. Dr. Bessen brings over 20 years in medical affairs, having launched 11 products at Bristol Myers Squibb. Dr. Grogan, an expert in drug development, has held leadership roles at multiple biopharmaceutical firms. Their appointments signify C4T's commitment to innovative therapies in oncology as it progresses multiple programs in clinical trials.
C4 Therapeutics (Nasdaq: CCCC) announced the dosing of the first patient in its Phase 1/2 clinical trial for CFT8634, a targeted treatment for SMARCB1-perturbed cancers, including synovial sarcoma. This BiDAC™ degrader targets BRD9, deemed 'undruggable.' The trial will focus on CFT8634's safety, tolerability, and anti-tumor activity, enrolling approximately 90 patients. CFT8634 has received orphan drug designation from the FDA, marking a significant advancement in C4T's oncology pipeline and potentially offering new options for patients with limited therapies.
C4 Therapeutics (Nasdaq: CCCC) reported Q1 2022 financial results, with total revenue of $7.7 million compared to $7.4 million in Q1 2021. R&D expenses rose to $26.2 million, up from $20.5 million year-over-year. The net loss increased to $31.6 million or $0.65 per share, compared to a $21.0 million loss in the prior year. As of March 31, 2022, cash, cash equivalents, and marketable securities totaled $421.7 million, expected to fund operations until late 2024. The company continues dose optimization trials for CFT7455 and has initiated a Phase 1/2 trial for CFT8634.
